Status:
COMPLETED
Magnesium Sulfate vs Placebo for Placental Abruption
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Santa Clara Valley Medical Center
Conditions:
Abruptio Placentae
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
To evaluate the safety and efficacy of magnesium sulfate for preterm suspected abruption.
Detailed Description
We hope to learn if there is a difference in the efficacy of intravenous magnesium sulfate versus intravenous saline infusion in the resolution of vaginal bleeding and contractions in patients with a ...
Eligibility Criteria
Inclusion
- \- vaginal bleeding and contractions consistent with suspected placental abruption between 24 and 34 weeks gestation.
Exclusion
- \- preterm labor, severe bleeding necessitating immediate delivery, maternal coagulopathy, fetal distress
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00186069
Start Date
March 1 2004
End Date
November 1 2017
Last Update
January 2 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Santa Clara Valley Medical Center
San Jose, California, United States, 95128
2
Stanford University School of Medicine
Stanford, California, United States, 94305